Related references
Note: Only part of the references are listed.The place for remdesivir in COVID-19 treatment
Barnaby Young et al.
LANCET INFECTIOUS DISEASES (2021)
Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation
Francesca Curreli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp et al.
SCIENCE (2020)
Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase
Quan Wang et al.
CELL (2020)
A Genomic Perspective on the Origin and Emergence of SARS-CoV-2
Yong-Zhen Zhang et al.
CELL (2020)
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
Vanessa Monteil et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies
Lillian B. Cohn et al.
CELL HOST & MICROBE (2020)
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
Shuai Xia et al.
CELL RESEARCH (2020)
Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance
Francesc Xavier Ruiz et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2020)
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Yan Gao et al.
SCIENCE (2020)
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Xiuyuan Ou et al.
NATURE COMMUNICATIONS (2020)
Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells
Xiaojie Su et al.
FRONTIERS IN MICROBIOLOGY (2020)
Structure of replicating SARS-CoV-2 polymerase
Hauke S. Hillen et al.
NATURE (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes
Tianshu Xiao et al.
NATURE CHEMICAL BIOLOGY (2020)
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Yadi Zhou et al.
CELL DISCOVERY (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19
Harmony R. Reynolds et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SnapShot: Enveloped Virus Entry
Jason Mercer et al.
CELL (2020)
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
Christopher O. Barnes et al.
CELL (2020)
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review
W. Joost Wiersinga et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells
Dorothea Bestle et al.
LIFE SCIENCE ALLIANCE (2020)
Emerging Pandemic Diseases: How We Got to COVID-19
David M. Morens et al.
CELL (2020)
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Brandi N. Williamson et al.
NATURE (2020)
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
Chengyuan Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Xiangyang Chi et al.
SCIENCE (2020)
An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells
Qian Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2
Alex Renn et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
Rodrigo Jacome et al.
SCIENTIFIC REPORTS (2020)
Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent D-peptide HIV entry inhibitor
Yoshiaki Nishimura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
Shuai Xia et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
Martin R. Gaudinski et al.
LANCET (2019)
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Marina Caskey et al.
NATURE MEDICINE (2019)
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption
Chang-Yi Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
Shuai Xia et al.
SCIENCE ADVANCES (2019)
Therapeutic strategies to target the Ebola virus life cycle
Thomas Hoenen et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
Robert N. Kirchdoerfer et al.
NATURE COMMUNICATIONS (2019)
A Structure-Function Diversity Survey of the RNA-Dependent RNA Polymerases From the Positive-Strand RNA Viruses
Hengxia Jia et al.
FRONTIERS IN MICROBIOLOGY (2019)
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Sabue Mulangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution
Sangita Venkataraman et al.
VIRUSES-BASEL (2018)
De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery
Chao Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
Brinda Emu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Recent progress in broadly neutralizing antibodies to HIV
Devin Sok et al.
NATURE IMMUNOLOGY (2018)
Repurposing Estrogen Receptor Antagonists for the Treatment of Infectious Disease
Marhiah C. Montoya et al.
MBIO (2018)
Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes
Longlong Si et al.
SCIENCE ADVANCES (2018)
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
Laura M. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein
Melissanne de Wispelaere et al.
CELL CHEMICAL BIOLOGY (2018)
Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol
Rameshwar U. Kadam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses
David J. Holthausen et al.
IMMUNITY (2017)
Influenza antivirals currently in late-phase clinical trial
Paulina Koszalka et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2017)
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529
Marie Pancera et al.
NATURE CHEMICAL BIOLOGY (2017)
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Veaceslav Boldescu et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
Yousuke Furuta et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2017)
Structural Biology of the Zika Virus
Yi Shi et al.
TRENDS IN BIOCHEMICAL SCIENCES (2017)
A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses
Yufeng Yu et al.
NATURE COMMUNICATIONS (2017)
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome
Akram Khan et al.
CRITICAL CARE (2017)
Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses
Anna Z. Wec et al.
CELL (2017)
Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability
Xuelian Zhao et al.
CELL (2017)
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico
Davide F. Robbiani et al.
CELL (2017)
Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors
Manu Anantpadma et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Approved Antiviral Drugs over the Past 50 Years
Erik De Clercq et al.
CLINICAL MICROBIOLOGY REVIEWS (2016)
Hepatitis C virus NS3/4a protease inhibitors
John A. McCauley et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Nan Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
Thanigaimalai Pillaiyar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS
Arun K. Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al.
NATURE (2016)
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection
Richard T. Davey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor
Jian Lei et al.
SCIENCE (2016)
Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody
Rui Kong et al.
SCIENCE (2016)
Improving Viral Protease Inhibitors to Counter Drug Resistance
Nese Kurt Yilmaz et al.
TRENDS IN MICROBIOLOGY (2016)
Climate Change and Respiratory Infections
Mehdi Mirsaeidi et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2016)
The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds
Yahira M. Baez-Santos et al.
ANTIVIRAL RESEARCH (2015)
Structural basis for RNA replication by the hepatitis C virus polymerase
Todd C. Appleby et al.
SCIENCE (2015)
Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance
Auda A. Eltahla et al.
VIRUSES-BASEL (2015)
Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein
Jean Kaoru Millet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
Lu Lu et al.
NATURE COMMUNICATIONS (2014)
Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance
Stephanie Beaucourt et al.
CURRENT OPINION IN VIROLOGY (2014)
HIV-1 reverse transcriptase and antiviral drug resistance. Part 1
Kalyan Das et al.
CURRENT OPINION IN VIROLOGY (2013)
The newly emerged SARS-Like coronavirus HCoV-EMC also has an Achilles' heel: current effective inhibitor targeting a 3C-like protease
Zhilin Ren et al.
PROTEIN & CELL (2013)
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Jinghe Huang et al.
NATURE (2012)
The structural biology of HIV-1: mechanistic and therapeutic insights
Alan Engelman et al.
NATURE REVIEWS MICROBIOLOGY (2012)
Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza
Hideyuki Ikematsu et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2011)
Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes
Emily Happy Miller et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Design, Synthesis, and Biological Activity of Novel 5-((Arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 Fusion Inhibitors Targeting gp41
Shibo Jiang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and Long In Vivo Half-Life
Dong Xie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Challenges in modern drug discovery: A case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection
F. George Njoroge et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
The flavivirus polymerase as a target for drug discovery
Helene Malet et al.
ANTIVIRAL RESEARCH (2008)
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor
Jeffrey E. Lee et al.
NATURE (2008)
Recent anti-influenza strategies in multivalent sialyloligosaccharides and sialylmimetics approaches
Xue-Long Sun
CURRENT MEDICINAL CHEMISTRY (2007)
Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus
P Erbel et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus
KM Lip et al.
JOURNAL OF VIROLOGY (2006)
Design of wide-spectrum inhibitors targeting coronavirus main proteases
HT Yang et al.
PLOS BIOLOGY (2005)
Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors
SW Liu et al.
LANCET (2004)
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542
JM Jacobson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor
HT Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41
MB Zwick et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
